Bristol-Myers Squibb combines strong cash generation with a broadening growth portfolio, but legacy-product dependence and debt keep the story balanced. The stock looks attractive on valuation, with Eliquis and newer launches helping offset patent pressure.
Bristol-Myers Squibb (BMY) is a Buy for moderate-risk investors seeking a medium-term combination of cash generation, portfolio renewal, and valuation support. The investment case rests on three facts: BMY generated $48.2B of 2025 revenue, produced $12.9B of free cash flow, and is scaling a growth portfolio that represented nearly 60% of Q2 2026 revenue. The counterweight is substantial debt and continued reliance on Eliquis, Opdivo, and other mature brands.
The business is moving through a patent and product transition rather than a simple growth cycle. Eliquis generated $14.4B in 2025 revenue, while Opdivo generated $10.0B. At the same time, Q2 2026 growth was broad: Reblozyl grew 29%, Breyanzi 41%, Camzyos 59%, and Cobenfy 81%. That breadth gives BMY a credible bridge from legacy blockbusters to newer medicines.
The main risk is that analyst estimates show EPS peaking near $6.61 in 2027 before falling to $5.29 in 2028 and $4.81 in 2029. BMY therefore deserves a discount to faster-growing pharmaceutical peers, but its 9.4x forward P/E, 12.5% FCF yield, and $65.25 analyst target provide a valuation cushion. The result is a constructive view with a clear requirement: the growth portfolio must keep expanding while management reduces balance-sheet pressure.
Bristol-Myers Squibb is a global biopharmaceutical company founded in 1887 and headquartered in Princeton, New Jersey. It employed approximately 32,500 people and operated across oncology, hematology, immunology, cardiovascular medicine, and neuroscience. The company discovers, develops, manufactures, licenses, markets, and distributes prescription medicines through a global commercial network.
BMY's product portfolio spans established blockbusters and newer therapies. Its commercial base includes Eliquis, Opdivo, Orencia, Revlimid, Yervoy, Pomalyst, Reblozyl, Breyanzi, Opdualag, Camzyos, Sotyktu, and Cobenfy. The 2025 product mix shows the scale of the franchise: Eliquis accounted for 30.0% of revenue, Opdivo 20.9%, Orencia 7.7%, and Yervoy 6.0%.
The company is also reshaping its operating model. CEO Christopher Boerner said BMY had made progress toward a more agile and efficient organization, while management has expanded the use of artificial intelligence through partnerships with Anthropic and NVIDIA. The objective is practical rather than fashionable: faster molecule design, deeper disease analysis, and earlier decisions on which programs deserve further investment.
BMY reports as a single operating segment, but its investment profile is best understood through growth and legacy portfolios. In Q2 2026, growth portfolio revenue rose 14% to $7.6B and represented nearly 60% of total revenue. Total quarterly revenue increased 5% to approximately $13.0B, with newer medicines offsetting declines across older products.
The growth portfolio is broadening. Reblozyl reached $2.3B of 2025 revenue and grew 29% in Q2 2026. Breyanzi generated $1.4B in 2025 and posted 41% quarterly growth. Camzyos generated $1.1B in 2025 and rose 59% to $416M in Q2. Cobenfy remains small at $155M of 2025 revenue, but quarterly revenue grew 81% to $63M.
The legacy portfolio remains economically important. Eliquis, Revlimid, Pomalyst, and other established medicines still provide large cash flows, even as generic entry pressures several brands. Management's Q2 guidance called for a 4% to 6% decline in the total legacy portfolio, an improvement from the earlier outlook, while Eliquis growth was raised to 20% to 25% for 2026.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Eliquis is BMY's financial anchor. The anticoagulant produced $14.4B of 2025 revenue, or 30.0% of the company total. Q2 2026 revenue was approximately $4.5B, up 21%, driven by demand and continued market-share gains. That performance nearly offset declines from generic entry across the rest of the legacy portfolio.
Eliquis also demonstrates both the strength and the concentration risk in BMY's model. The product's scale supports cash generation and commercial leverage, while the 2026 price decrease and government-channel dynamics put pressure on reported revenue. Management's expectation for 20% to 25% growth in 2026 provides important near-term support, but the long-term investment case cannot depend on one anticoagulant carrying the entire portfolio.
Opdivo is the other major pillar. It generated $10.0B in 2025 revenue, but Q2 2026 revenue fell 4% to approximately $2.5B as U.S. patients converted to Qvantig. Qvantig generated $261M in Q2 and was annualizing above $1B. This is a product transition inside the franchise rather than a clean loss of oncology demand, although the shift creates execution risk while physicians and payers adjust.
BMY's strongest competitive advantage is the combination of scientific depth, regulatory experience, and global commercialization. The company spent $10.0B on research and development in 2025 and is applying that platform across cell therapy, protein degraders, antibody-drug conjugates, radiopharmaceuticals, and neuroscience.
The pipeline includes iberdomide and mezigdomide in the CELMoD class, with mezigdomide carrying a May 13, 2027 PDUFA date. BMY also reported positive pivotal data for admilparant, RYZ101, arlo-cel, and Zenbexus-related programs in its 2026 investor materials. Management has identified more than 30 lifecycle-management opportunities through the end of the decade.
Patent protection adds durability to selected growth assets. The 2025 10-K estimated U.S. patent expiries around 2033 for Reblozyl and 2036 for Camzyos and Sotyktu, while Cobenfy's combination patent was estimated to expire in 2030 with a potential extension. Those dates do not eliminate clinical or pricing risk, but they support the commercial runway for newer brands.
BMY sells through wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. That channel breadth supports global reach but also makes reimbursement, inventory, and market-access execution central to results. The Q2 transcript noted wholesale inventory movement in Opdivo, a reminder that reported sales can differ from underlying patient demand.
The company is using productivity initiatives to fund growth rather than simply cutting investment. Q2 2026 operating expenses were $4.1B, gross margin was 71.4%, and management said productivity savings created flexibility for pipeline programs and launches. BMY also generated approximately $3.4B of operating cash flow in Q2 and paid down $1.2B of debt.
Supply-chain resilience remains linked to regulatory and geopolitical conditions. BMY's 2025 10-K identified state and federal efforts to increase rebates or limit drug spending as risks to pricing and market access. The company therefore needs both reliable manufacturing and a commercial system capable of navigating changing reimbursement rules.
The global pharmaceutical market was estimated at $1.77T in 2025 and is projected to reach $2.67T by 2031, representing a 7.0% compound annual growth rate. Prescription drugs represented 86.6% of the market in 2025. This creates a large structural market, but growth is concentrated in areas where clinical differentiation and payer access remain strong.
Oncology is especially important to BMY. Global cancer medicine spending reached $252B in 2024 and is projected to rise to $441B by 2029. Antibody-drug conjugates, bispecifics, and cell therapies are gaining share of innovation activity. BMY's oncology exposure through Opdivo, Yervoy, Opdualag, Qvantig, Breyanzi, and its pipeline aligns with that market expansion.
The market also rewards companies that can manage mature products while funding new science. BMY's 14% Q2 growth in the growth portfolio demonstrates that it is participating in the expanding part of the market, while Eliquis and other legacy brands provide the cash base needed to finance launches and acquisitions.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
BMY's direct commercial customers are healthcare institutions and intermediaries rather than individual consumers. Wholesalers, specialty pharmacies, hospitals, clinics, government agencies, and insurers influence product access, while physicians determine prescribing and patients determine persistence. This creates a layered decision process in which efficacy alone does not guarantee adoption.
Eliquis illustrates the scale of the cardiovascular customer base. Management cited approximately 10 million diagnosed and treated atrial-fibrillation patients in the U.S. and said roughly 40% of patients who should be anticoagulated are undertreated, underdosed, or discontinued. The figure supports a large unmet-need opportunity for Eliquis and the milvexian pipeline.
Cobenfy shows the behavioral side of adoption. Q2 total prescriptions increased about 15% quarter over quarter, with more new prescribers, but management also said new patient starts and repeat prescribing need to improve. The company is educating physicians to titrate patients toward the 125-milligram dose, making physician confidence and treatment habits important drivers of future uptake.
BMY competes with large global pharmaceutical companies, focused biotechnology firms, and generic manufacturers. Its named comparator group includes AbbVie, Amgen, AstraZeneca, Gilead, GSK, Johnson & Johnson, Eli Lilly, Merck, Novartis, Pfizer, Regeneron, Roche, and Sanofi.
In oncology and immuno-oncology, Merck, Roche, AstraZeneca, Pfizer, Johnson & Johnson, Novartis, Gilead, and Regeneron compete for indications, physician preference, and clinical-trial leadership. In immunology, AbbVie, Johnson & Johnson, Novartis, Sanofi, Roche, and GSK are major rivals. Cardiovascular competition includes Johnson & Johnson, Pfizer, Novartis, Sanofi, AstraZeneca, and Merck.
BMY's advantage is concentrated in franchises where it combines a recognized standard of care with lifecycle opportunities. Its weakness is that many of those markets are crowded, and the 2025 10-K explicitly described competition as intense. The company must keep producing superior data, secure new indications, and convert pipeline assets into commercial products before mature-brand erosion accelerates.
Pricing policy is the most direct macro risk for BMY. The 2025 10-K identified federal and state efforts to increase rebates, limit spending, and constrain drug pricing. The Inflation Reduction Act remains a central policy issue for large pharmaceutical companies, while European market access is shaped by health-technology assessment and the European Union's pharmaceutical legislation.
Generic and biosimilar competition adds a second structural headwind. BMY's Revlimid revenue remained resilient despite full generic availability in the U.S., but the company's guidance still includes legacy portfolio declines. That pattern shows why the growth portfolio matters: pricing pressure and loss of exclusivity can affect mature products faster than new launches can replace them.
Aging populations, chronic disease prevalence, and rising oncology spending support long-term demand. At the same time, Deloitte has identified geopolitical volatility, manufacturing risk, pricing pressure, and access challenges as persistent life-sciences headwinds. BMY's low beta of 0.2 gives the stock a defensive market profile, but policy changes can still create sharp company-specific earnings effects.
Net debt remains a key overhang, but BMY's $12.9B of free cash flow and strong operating cash generation give it meaningful flexibility to manage leverage.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →2025 revenue reached $48.2B, with Eliquis at $14.4B and Opdivo at $10.0B, while the growth portfolio already represented nearly 60% of Q2 2026 revenue.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Analysts see EPS peaking near $6.61 in 2027 before easing to $5.29 in 2028 and $4.81 in 2029, highlighting the challenge of sustaining growth beyond the current launch cycle.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →BMY trades at 9.4x forward P/E with a 12.5% FCF yield, a discount that reflects patent risk but also leaves a valuation cushion versus faster-growing pharma peers.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The $65.25 analyst target sits above the current valuation case, implying the market is still underappreciating the cash flow base and the expanding growth portfolio.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Bristol-Myers Squibb offers a credible value-and-renewal story. Eliquis remains a powerful cash generator, the growth portfolio rose 14% in Q2 2026, and products such as Reblozyl, Breyanzi, Camzyos, and Cobenfy are gaining scale. Annual free cash flow of $12.9B gives management resources to reduce debt, invest in research, and support the dividend.
The risks are equally concrete: $43.1B of quarterly debt, a 2.5 annual debt-to-equity ratio, intense competition, pricing policy, and analyst estimates that decline after 2027. BMY is not a clean high-growth compounder. It is a large pharmaceutical transition story priced with enough skepticism to merit a Buy rating, provided investors accept that pipeline execution and balance-sheet improvement must advance together.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Bristol-Myers Squibb Company (BMY) gains after a deep Q3 earnings review showing beats on EPS and revenue, stronger growth-brand sales, and raised revenue guidance. The analysis also weighs margin pressure, lower EPS guidance, and the ongoing shift away from legacy products.
Bristol-Myers Squibb Company (BMY) slips 0.6% even after posting earnings beats, as investors weigh the latest results against broader market sentiment.
CoreWeave, Inc. Class A Common Stock (CRWV) jumps after a strong earnings report that topped EPS estimates, delivered $3.66B in quarterly revenue, and raised 2026 guidance. The move reflects renewed confidence in AI infrastructure demand, though investors still face volatility, negative earnings, and capital-intensity risks.